Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Why Amarin Stock May Rise From Here
12:31am, Wednesday, 23'rd Jun 2021
Amarin stock surpassed the 75% upside price target in Feb., only to fall from there. Unfavorable Patent ruling expected.
Why Amarin Fell Again Today
06:13pm, Tuesday, 22'nd Jun 2021
Another Vascepa generic is launched in the U.S.
Why Amarin Stock Is Sinking Today
11:30am, Monday, 21'st Jun 2021
The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.
7 Hot Penny Stocks to Watch That Are Trending Right Now
07:36pm, Sunday, 20'th Jun 2021
Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News
Best Penny Stocks To Buy Now? 7 To Watch This Week
01:09pm, Sunday, 20'th Jun 2021
What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
Amarin Corporation plc (AMRN) CEO John Thero Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
01:59pm, Tuesday, 08'th Jun 2021
Amarin Corporation plc (AMRN) CEO John Thero Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Eu
Amarin Corporation's (AMRN) CEO John Thero on Jefferies Virtual Healthcare Conference - Transcript
01:45pm, Wednesday, 02'nd Jun 2021
Amarin Corporation's (AMRN) CEO John Thero on Jefferies Virtual Healthcare Conference - Transcript
Why Amarin Trounced the Market on Tuesday
06:19pm, Tuesday, 18'th May 2021
Investors reacted positively to a company presentation at an industry convention.
Amarin to Present at Two Investor Conferences in June 2021
06:05am, Tuesday, 18'th May 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Kar
REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology's 70th Annual Scientific Session
08:00am, Saturday, 15'th May 2021
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher
Why Amarin Stock Is Tumbling Today
11:03am, Wednesday, 12'th May 2021
An analyst downgraded the drugmaker.
Amarin Corporation PLC (AMRN) CEO John Thero on Q1 2021 Results - Earnings Call Transcript
02:21pm, Thursday, 29'th Apr 2021
Amarin Corporation PLC (AMRN) CEO John Thero on Q1 2021 Results - Earnings Call Transcript
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
12:47pm, Thursday, 29'th Apr 2021
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line.
